One study showed that in GBM-bearing mice, depleting MDSCs using the antibody against Gr1, an immune marker for mouse MDSCs, strongly enhanced the efficacy of tumor-targeted gene therapy, and when combined with anti-PD-L1 or CTLA-4 treatment, greatly improved overall animal survival [164]. Here, CD274 is linked to glioblastoma.